Regulatory press releases

In accordance with the decision taken at the annual general meeting on May 27, 2021, the three largest shareholders as of September 30, 2021 have been contacted by the chairman of the board and been offered to appoint a member each to the nomination committee of Nanologica AB. The three largest shareholders as of September 30, 2021 have each appointed one representative so that the nomination committee for the annual general meeting 2022 consists of

Nanologica AB has decided to close the project with the drug candidate NIC-001 for the treatment of gastroparesis before the planned clinical study begins, in order to focus the company’s resources on the continued development of the inhalation platform NLAB Spiro®. The closure of the project is a result of the company’s strategy in the drug development business area being refined to focus on inhalation and respiratory diseases, and because the commercial conditions for NIC-001

CEO Andreas Bhagwani has privately and through his company Vega Bianca AB divested 323,000 shares in Nanologica AB for private economic reasons. At the same time, he exercised 227,566 options to shares. Following the transactions, Andreas Bhagwani’s holdings in Nanologica AB amounts to 2,019,764 shares, equivalent to 7.3 percent of the total number of shares in Nanologica, and 165,000 options. “The sale is made for personal economic reasons. Nanologica remains my largest investment and commitment,